Pacific Biosciences of California, Inc.
DB:P09 Stock Report
Pacific Biosciences of California Past Earnings Performance Pacific Biosciences of California's earnings have been declining at an average annual rate of -40.2%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 18.7% per year.
Key information
-40.2%
Earnings growth rate
Life Sciences Industry Growth 26.8% Revenue growth rate 18.7% Return on equity -87.0% Net Margin -227.7% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023) Nov 09
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11 Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024 Aug 08
Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 16
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023) May 11
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Mar 04
Show all updates
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023) Nov 09
PacBio Unveils the Vega System Nov 07
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems Oct 29
Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
President recently sold €155k worth of stock Sep 19
Chief Operating Officer recently sold €57k worth of stock Aug 22 Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024 Aug 08
Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 16
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index Jul 03
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023) May 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024 May 01
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 Apr 16
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions Mar 12
Insider recently bought €162k worth of stock Mar 07
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Mar 04
President recently sold €445k worth of stock Feb 25
Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022) Feb 16
Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale Feb 05
Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions Jan 15
Chief Operating Officer recently sold €221k worth of stock Jan 12
Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board Dec 12
PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders Nov 04
Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022) Nov 01
Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee Oct 28
Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors Oct 17
Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 13
Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis Oct 12
President recently sold €918k worth of stock Sep 21
Chief Operating Officer recently sold €263k worth of stock Aug 20
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million. Aug 04
Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022) Aug 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.
Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 22
Now 25% undervalued Jun 16 Pacific Biosciences of California, Inc. Announces Board Changes
VP & Chief Accounting Officer recently sold €60k worth of stock May 23
Insufficient new directors May 09
Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021) Feb 19
PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions Feb 08
Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Insufficient new directors Jan 26 Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 26
Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. Jan 25
Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022
Pacific Biosciences of California, Inc. Announces Board Appointments Nov 03
Pacific Biosciences of California, Inc. Withdraws its Financial Guidance Oct 27 Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022
PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery Oct 21
PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing Oct 20
Chief Financial Officer recently sold €75k worth of stock Oct 04
PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis Sep 28
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021) Aug 04
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 04
Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022 Jul 22
Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 19
Pacific Biosciences of California, Inc. Announces Management Changes May 19
First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021) May 06
Insufficient new directors Apr 27
Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022 Apr 15
Insufficient new directors Apr 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022 Feb 02
Chief Operating Officer recently sold €519k worth of stock Jan 14
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021 Jan 12
PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants Dec 29
Insufficient new directors Dec 06
Third quarter 2021 earnings released: EPS US$0.082 (vs US$0.14 loss in 3Q 2020) Nov 03 Pacific Biosciences of California, Inc. (NasdaqGS:PACB) completed the acquisition of Omniome, Inc.
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) acquired Circulomics, Inc. Aug 05
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2020) Aug 04
Senior Fellow & Director Michael Hunkapiller has left the company Jun 18
VP & Chief Accounting Officer has left the company May 19
First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.008 profit in 1Q 2020) May 01
Pacific Biosciences of California, Inc. Launches New HiFi Sequencing Workflow Apr 27
Revenue beats expectations Mar 02
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Mar 02
VP & Chief Accounting Officer recently sold €124k worth of stock Feb 27
Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19 Feb 19
Independent Director recently sold €4.2m worth of stock Feb 19
Pacific Biosciences of California, Inc. announced that it has received $900 million in funding from SB Northstar LP Feb 18
Full year 2020 earnings released: EPS US$0.18 (vs US$0.55 loss in FY 2019) Feb 12
Revenue beats expectations Feb 12
New 90-day high: €42.00 Feb 12
Pacific Biosciences of California, Inc. announced that it expects to receive $900 million in funding from SB Northstar LP Feb 11
Pacific Biosciences of California, Inc., Annual General Meeting, Jun 16, 2021 Feb 10
Senior Fellow & Director recently sold €1.5m worth of stock Jan 24
Revenue & Expenses Breakdown
How Pacific Biosciences of California makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History DB:P09 Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 173 -394 165 146 30 Jun 24 189 -400 172 168 31 Mar 24 200 -297 174 182 31 Dec 23 201 -307 170 187 30 Sep 23 170 -309 169 185 30 Jun 23 146 -319 162 185 31 Mar 23 134 -321 161 189 31 Dec 22 128 -314 161 193 30 Sep 22 137 -299 153 193 30 Jun 22 140 -206 148 173 31 Mar 22 135 -175 138 145 31 Dec 21 131 -181 124 113 30 Sep 21 122 -37 105 88 30 Jun 21 106 -77 94 77 31 Mar 21 92 -59 80 69 31 Dec 20 79 29 73 64 30 Sep 20 80 -46 84 61 30 Jun 20 83 -51 71 59 31 Mar 20 90 -53 75 59 31 Dec 19 91 -84 75 60 30 Sep 19 82 -115 62 62 30 Jun 19 79 -111 68 61 31 Mar 19 76 -109 64 62 31 Dec 18 79 -103 63 63 30 Sep 18 84 -93 58 62 30 Jun 18 89 -90 58 63 31 Mar 18 88 -93 59 65 31 Dec 17 93 -92 59 65 30 Sep 17 94 -90 58 66 30 Jun 17 96 -86 56 68 31 Mar 17 97 -79 51 68 31 Dec 16 91 -74 48 68 30 Sep 16 101 -57 48 66 30 Jun 16 90 -37 46 65 31 Mar 16 94 -31 46 62 31 Dec 15 93 -32 45 60 30 Sep 15 73 -49 42 58 30 Jun 15 80 -60 41 54 31 Mar 15 67 -67 40 51 31 Dec 14 61 -66 38 48 30 Sep 14 53 -64 37 47 30 Jun 14 40 -76 38 46 31 Mar 14 34 -77 38 45 31 Dec 13 28 -79 39 45
Quality Earnings: P09 is currently unprofitable.
Growing Profit Margin: P09 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: P09 is unprofitable, and losses have increased over the past 5 years at a rate of 40.2% per year.
Accelerating Growth: Unable to compare P09's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: P09 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: P09 has a negative Return on Equity (-87.01%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}